IGF1 and breast cancer: Here we demonstrate that a relatively potent and selective PDK1 inhibitor, PF-5177624, is able to inhibit IGF-I induced phosphorylation of downstream signaling molecules, block cell cycle progression, and decrease cell proliferation and transformation in luminal breast cancer cells.